Articles tagged with Lung Cancer
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
A panel of experts has issued new guidelines for molecular diagnostic testing and treatment decisions in lung cancer. The updates reflect recent advancements and decades of work to identify the genetic underpinnings of lung cancer, helping oncologists match patients with effective therapies.
A University of Colorado Cancer Center study found low post-treatment mortality rates for both surgery and targeted radiation in early-stage lung cancer patients. Patients over 80 years old showed significantly higher mortality rates with surgery compared to targeted radiation.
A new Michigan State University study finds that mice can mimic human breast cancer tissue and genes, as well as other cancers including lung, oral, and esophagus. This breakthrough could lead to more effective treatments by identifying similarities between tumors.
A large study has found a significant link between severe gum disease and an increased risk of cancer, particularly lung and colorectal cancer. The study, which used data from over 7,400 participants, found that those with advanced gum disease were 24% more likely to develop cancer than those without.
RAS molecules act in pairs, known as dimers, to cause cancer and transmit signals that tell a cell to grow and divide. The study provides a foundation for further studies on RAS biology and could potentially pave the way to develop new cancer drugs.
Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival when treated with chemoradiation compared to definitive radiation alone. Treatment with concurrent or sequential CRT was associated with a 33% reduction in the risk of death.
A research team at Rush University Medical Center is working on a simple blood test to detect non-small cell lung cancer with 90% accuracy. The goal is to identify biomarkers that can detect the disease earlier and reduce late-stage diagnoses, improving treatment outcomes.
A new study reveals significant healthcare disparities among patients aged 80 and older with advanced lung cancer. African Americans and those from lower-income areas are more likely to not receive standard care therapy, leading to poorer outcomes. In contrast, patients receiving standard treatment live longer.
The US cancer death rate has dropped 26% since its peak in 1991, resulting in nearly 2.4 million fewer cancer deaths. This decline is mainly due to reductions in smoking and advances in early detection and treatment.
Individualized risk-based lung cancer screening using calculators that account for demographic and clinical characteristics may save more lives than current USPSTF recommendations. Researchers estimate that this approach could have prevented over 5,000 more deaths in 2015 compared to the current guidelines.
Smokers with targetable genetic alterations in their lung cancer benefit equally from targeted therapies as non-smokers. Targeted treatments improve survival by 1.5 years, regardless of smoking status.
Studies using mouse models of lung cancer found that neutrophils help tumors hide from T cells and promote their own growth through the production of Snail protein. This 'vicious cycle' between neutrophils and tumor cells hinders immunotherapy's effectiveness in up to two-thirds of patients.
A new study by Voskarides suggests that genetic variants beneficial for survival at extreme temperatures can predispose individuals to cancer. The study analyzes the relationship between cancer risk and local average annual temperatures, concluding that extremely cold environments contribute to cancer risk.
Differences in gene expression between non-small cell lung cancers from African-Americans and European-Americans suggest racial disparities in NSCLC biology. The study identified distinct patterns of gene expression involved in stem cell biology and invasive behavior in African-American NSCLCs.
Researchers at Johns Hopkins Kimmel Cancer Center have identified a novel drug combination that can prime nonsmall cell lung cancers to respond better to immunotherapy. The treatment, which combines a demethylating drug with an HDAC inhibitor, triggered a chemical cascade that increased the attraction of immune cells to fight tumors an...
Researchers have identified a communication network between lung tumors and bone marrow that contributes to tumor progression. Tumors activate osteoblasts in the bone marrow, leading to the production of immune cells that promote cancer growth.
Research reveals that bone marrow-derived cells contribute to lung cancer progression by stimulating the production of specific neutrophils. These neutrophils exhibit increased expression of genes associated with tumor-promoting processes, leading to worse patient survival in a small study.
A recent study published in Cancer journal shows that communities with strong smoke-free workplace laws have lower rates of new lung cancer diagnoses. The study found an eight percent reduction in lung cancer incidence in communities with strong smoke-free laws compared to those without such laws.
Leading lung cancer specialists call for immediate action to implement life-saving lung cancer screening programmes across Europe. The EU Position Statement on Lung Cancer Screening provides a detailed set of recommendations and a 'Call to Action' for policymakers to start planning within the next 18 months.
A study published in Science Translational Medicine found that lung cancer often leads to pulmonary hypertension due to immune cell activation and inflammatory processes triggered by cancer cells. This discovery could lead to new therapeutic approaches for developing a treatment.
A subset analysis of the FLAURA trial found that osimertinib improved progression-free survival by 16.5 months compared to 11.0 months with standard therapy in Asian patients with EGFR-mutated non-small-cell lung cancer, resulting in a hazard ratio of 0.54.
Researchers analyzed EGFR mutation status in blood and cerebrospinal fluid to identify relationship with neurological symptoms and leptomeningeal metastases. The study found higher rates of EGFR mutations in cerebrospinal fluid for patients with brain metastases, offering new non-invasive testing options.
A UK study published in Scientific Reports has identified a novel cell signaling interaction that may prevent a key step in lung cancer progression. The research, conducted by the University of Kentucky, found that microRNA molecules can alter TGFβ activity and prevent epithelial-mesenchymal transition, a critical process in metastasis.
A research team led by BU School of Medicine professor Avrum Spira is developing diagnostic tools to intercept lung cancer at its earliest stage using innovative approaches like nasal swabs and blood tests. The goal is to confirm whether lung abnormalities found on chest imaging are benign lung disease or signs of cancer.
Researchers observed a significant association between warfarin use and reduced risk of new cancers, particularly prostate, lung, breast, and colon cancers. The findings suggest that warfarin may be protective against certain types of cancer, which could have implications for anticoagulation treatment.
A new study reveals that non-small cell lung cancers are driven by multiple genetic changes, including alterations in TP53 and other pathways. The findings suggest that combination therapies targeting these mutations may improve treatment outcomes and prevent drug resistance.
Researchers found that cell-free tumor DNA circulating in the bloodstream correlates with tumor metabolism rather than tumor burden in advanced non-small cell lung cancer patients. This study suggests that circulating tumor DNA may be a reliable biomarker to identify potential unresponsive NSCLC patients before treatment.
A large-scale epidemiological study has associated certain air pollutants with increased mortality from kidney, bladder, and colorectal cancers. The study followed over 600,000 adults in the US and found that exposure to PM2.5, nitrogen dioxide, and ozone was linked to higher cancer death rates.
Researchers from four top teams receive funding to tackle cancers of the lung and pancreas using a new 'interception' approach, targeting precancerous cells before they turn into cancer cells. The initiative aims to catch cancers early, when treatment is more successful.
The American College of Chest Physicians has introduced updated guidelines for low-dose CT lung cancer screening, focusing on asymptomatic smokers and former smokers aged 55-77 with 30 pack-years or more smoking history. The new recommendations aim to balance potential benefits and harms of screening.
Gender disparities are identified in lung cancer screening and care, with more female patients meeting high-risk criteria but not completing low-dose CT scans. Language barriers do not delay initiation of lung cancer care, according to a second study.
A feasibility trial of yoga therapy for people with advanced lung cancer and their caregivers found improvements in physical function, stamina, and mental health. The study also showed benefits for caregivers, including reduced fatigue and improved stamina while working.
A University of Colorado Cancer Center study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. Treated with FDA-approved drugs, the tumor responded dramatically. The study suggests that these non-sun-exposed melanomas may be more susceptible to targeted treatments.
A study published in The Lancet Public Health found that federal drinking water regulations reduced toxic exposure and protected human health. Compliance with the EPA regulation led to a decline of 17% in levels of urinary arsenic, resulting in an estimated reduction of over 200 cases of lung and bladder cancer every year.
The Terry Fox Research Institute study found that the Pan Can Lung Cancer Risk Prediction Model outperformed comparable models in detecting early-stage lung cancer. The model identified high-risk individuals and detected cancer early, saving lives.
A 12-week physical and psycho-social intervention improved functional capacity in advanced lung cancer patients, while also enhancing their quality of life. The study's findings suggest that exercise interventions can be a beneficial approach for these patients, reducing the burden on caregivers and improving overall well-being.
A community-based intervention called c-CARE improved cancer literacy and reduced disparate lung cancer outcomes among minority communities. The study found that participants showed increased knowledge and self-efficacy for lung cancer screening, but not perceived susceptibility.
A study integrating smoking cessation programs with low-dose CT lung cancer screenings found that this approach can decrease mortality rates while being relatively cost-effective. The research suggests that adding a robust smoking cessation intervention to an organized LDCT screening program could result in significantly fewer deaths, ...
Researchers found that treating stage II and III non-small cell lung cancer (NSCLC) patients with chemotherapy based on their specific BRCA1 expression levels did not increase overall survival rates. However, BRCA1 expression levels were found to be prognostic, and individualized treatment could achieve different outcomes.
A study published in the IASLC 18th World Conference on Lung Cancer found that early specialist palliative care for recently diagnosed malignant pleural mesothelioma (MPM) patients does not impact quality of life. Researchers concluded that there is no role for routine early referral to palliative care, regardless of symptoms.
A study analyzing over 1.1 million NSCLC cases found significant disparities in survival rates based on race and socioeconomic factors such as education level and income. Patients of Asian and Hispanic backgrounds had better overall survival rates compared to Whites and Blacks.
Researchers confirmed IASLC's proposed criteria for uncertain resection margin status (R(un)) have a prognostic value between R0 and R1. The study analyzed data from 14,712 patients and evaluated the impact of various factors on survival.
Researchers found that NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation, leading to increased invasiveness and poor clinical outcomes. Depletion of NatD suppresses EMT via repression of Slug expression, suggesting a new therapeutic target for cancer treatment.
Dr. Yuze Sun is developing an optofluidic gas-analyzing microsystem to detect biomarkers in human exhaled breath for early stage lung cancer detection. The technology aims to replace invasive biopsies and needle pokes with a non-invasive screening method.
PharmaMar's Phase I/II trial combining PM1183 with doxorubicin shows a progression-free survival of 5.3 months, surpassing historical data for topotecan. The study also reveals manageable adverse events with no mucositis or neuropathy, paving the way for the pivotal Phase III Atlantis trial.
A DNA variant in the DNMT3B gene is associated with an increased risk of nicotine dependence, as well as heavier smoking and a higher likelihood of developing lung cancer. The study, which analyzed over 38,600 participants, provides new insights into the genetic factors influencing addiction.
Researchers at CRI discover lactate acts as a fuel source for growing tumors, contradicting the nearly century-old Warburg effect. The finding has significant implications for therapies and imaging techniques for lung cancer.
Anti-RAS antibodies are a critical research tool, but their poor reliability limits replicable study results. Researchers identified selectively recognizing each of the four human RAS proteins only in Western blot assays.
A laboratory-based study discovered that an alcohol aversion drug can reverse chemotherapy resistance in non-small cell lung cancer. The researchers found that the drug, Disulfiram, inhibited ALDH activity, reducing tumour cell growth and killing lung cancer stem cells.
A study found that mutations in the KEAP1 gene make lung adenocarcinoma cells vulnerable to oxidative stress, allowing an experimental drug called CB-839 to stop tumor growth. The discovery could lead to a more effective treatment for patients with combined KRAS and KEAP1 mutations.
Researchers used a proteomics platform to identify proteins with reactive cysteines in non-small-cell lung cancer cells, which could be targeted by drugs. The study found that targeting the protein NR0B1 reduced abnormal growth in NRF2-activated lung cancers.
A pilot program using big data predicts ED visits in lung cancer patients with 33% accuracy. The model identifies high-risk patients who are 6.6 times more likely to visit the ED compared to low-risk patients.
A phase III trial demonstrates a 32 percent overall survival rate at five years, setting a new benchmark for patients with inoperable stage III NSCLC. The trial also confirms that using a higher radiation dose is not beneficial and can lead to detrimental outcomes.
A recent study led by Massachusetts General Hospital estimates that nearly 10% of people with HIV currently in care in the US will die from lung cancer. Quitting smoking is crucial for reducing the risk of lung cancer and other diseases among people with HIV.
A new study projects increased lung cancer death risks among people living with HIV who smoke, with heavy smokers facing the highest mortality rates. The study suggests that tobacco use accelerates lung cancer development and should be prioritized in comprehensive care for HIV patients.
Researchers at Brigham and Women's Hospital discovered a rare genetic mutation in the ALK gene that causes peritoneal mesothelioma in young women with no history of asbestos or radiation therapy. Targeted therapy using FDA-approved drugs may be effective in treating these patients.
A study of British general practitioners found that physicians are more likely to support smoking cessation in primary care patients with coronary heart disease. Cancer patients are less likely to stop smoking due to lack of recording and advice from their doctors.
Researchers have identified a molecule called miR-124 in non-small cell lung cancer cells that plays a regulatory role in programmed cell death. The findings may offer a new target in the fight against non-small cell lung cancer, particularly for mesenchymal-like cells resistant to chemotherapy.
Researchers found that chronic cigarette smoke exposure leads to epigenetic changes in lung cells, silencing protective genes and priming them for cancer. These changes can be reversed by quitting smoking, suggesting a potential strategy for reducing lung cancer risk.